Cargando…

2297. COVID-19 Vaccine Effectiveness Among Pregnant People

BACKGROUND: COVID-19 presents a serious health risk to pregnant people and pregnancy outcomes. However, pregnant people were not included in pivotal phase III COVID-19 vaccine efficacy trials. METHODS: We used Cox regression models in a cohort study to determine hazard ratios (HR) of a PCR positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Zerbo, Ousseny, Thomas Ray, G, Goddard, Kristin, Layefsky, Evan, Fireman, Bruce, Klein, Nicola P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752373/
http://dx.doi.org/10.1093/ofid/ofac492.135
_version_ 1784850706206818304
author Zerbo, Ousseny
Thomas Ray, G
Goddard, Kristin
Layefsky, Evan
Fireman, Bruce
Klein, Nicola P
author_facet Zerbo, Ousseny
Thomas Ray, G
Goddard, Kristin
Layefsky, Evan
Fireman, Bruce
Klein, Nicola P
author_sort Zerbo, Ousseny
collection PubMed
description BACKGROUND: COVID-19 presents a serious health risk to pregnant people and pregnancy outcomes. However, pregnant people were not included in pivotal phase III COVID-19 vaccine efficacy trials. METHODS: We used Cox regression models in a cohort study to determine hazard ratios (HR) of a PCR positive test (“infection”) comparing vaccinated with unvaccinated pregnant persons in Kaiser Permanente Northern California. HRs were adjusted for age, race/ethnicity, type of insurance coverage, geographical area, BMI, preexisting diabetes, hypertension, parity, time since pregnancy onset and smoking status. Vaccine effectiveness (VE), calculated as 1 minus adjusted HR, was estimated for fully vaccinated < 150 and ≥ 150 days prior to infection. VE was estimated for before and during Delta, and Omicron. We also calculated incidence rates of COVID-pneumonia associated hospitalization by vaccination status. RESULTS: Among 68836 pregnancies between 12/15/2020 and 3/31/2022, 21834 (31.7%) were fully vaccinated and 5980 (8.7%) were boosted by the end of pregnancy. Compared with unvaccinated persons, the HRs of infection for fully vaccinated < 150 days prior were 0.13 (95% CI: 0.07 – 0.23; VE=87% [77% - 93%]) before Delta; 0.25 (CI: 0.20 – 0.30; VE=75% [70% - 80%]) during Delta and 0.76 (CI: 0.61 – 0.94; VE= 24% [16% - 39%]) during Omicron. The HRs for ≥ 150 days prior were 0.38 (CI: 0.31 – 0.46; VE=62 % [54% - 69%]) during Delta and 1.04 (CI: 0.89 – 1.22; VE= -0.04% [-0.22% – 0.11%]) during Omicron. The HRs for boosted persons were 0.10 (CI: 0.04 – 0.25; VE= 90% [75% - 96%]) during Delta and 0.42 (CI: 0.34 – 0.52; VE=58% [48% - 66%]) during Omicron periods. Incidence rates (IR) per 1000 person-years for hospitalization before delta were 0.75 among unvaccinated and zero among vaccinated. During Delta, the IR was 6.64 for unvaccinated and zero for fully vaccinated and boosted. During Omicron, the IR was 10.27 for unvaccinated, zero for fully vaccinated < 150 days prior, 2.48 for fully vaccinated ≥ 150 days prior and zero for those boosted. CONCLUSION: COVID-19 vaccines protect against infection and hospitalization among pregnant people. However, vaccine effectiveness against infection wanes over time and was lower during Omicron. Booster doses are necessary for continuous protection. DISCLOSURES: All Authors: No reported disclosures.
format Online
Article
Text
id pubmed-9752373
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97523732022-12-16 2297. COVID-19 Vaccine Effectiveness Among Pregnant People Zerbo, Ousseny Thomas Ray, G Goddard, Kristin Layefsky, Evan Fireman, Bruce Klein, Nicola P Open Forum Infect Dis Abstracts BACKGROUND: COVID-19 presents a serious health risk to pregnant people and pregnancy outcomes. However, pregnant people were not included in pivotal phase III COVID-19 vaccine efficacy trials. METHODS: We used Cox regression models in a cohort study to determine hazard ratios (HR) of a PCR positive test (“infection”) comparing vaccinated with unvaccinated pregnant persons in Kaiser Permanente Northern California. HRs were adjusted for age, race/ethnicity, type of insurance coverage, geographical area, BMI, preexisting diabetes, hypertension, parity, time since pregnancy onset and smoking status. Vaccine effectiveness (VE), calculated as 1 minus adjusted HR, was estimated for fully vaccinated < 150 and ≥ 150 days prior to infection. VE was estimated for before and during Delta, and Omicron. We also calculated incidence rates of COVID-pneumonia associated hospitalization by vaccination status. RESULTS: Among 68836 pregnancies between 12/15/2020 and 3/31/2022, 21834 (31.7%) were fully vaccinated and 5980 (8.7%) were boosted by the end of pregnancy. Compared with unvaccinated persons, the HRs of infection for fully vaccinated < 150 days prior were 0.13 (95% CI: 0.07 – 0.23; VE=87% [77% - 93%]) before Delta; 0.25 (CI: 0.20 – 0.30; VE=75% [70% - 80%]) during Delta and 0.76 (CI: 0.61 – 0.94; VE= 24% [16% - 39%]) during Omicron. The HRs for ≥ 150 days prior were 0.38 (CI: 0.31 – 0.46; VE=62 % [54% - 69%]) during Delta and 1.04 (CI: 0.89 – 1.22; VE= -0.04% [-0.22% – 0.11%]) during Omicron. The HRs for boosted persons were 0.10 (CI: 0.04 – 0.25; VE= 90% [75% - 96%]) during Delta and 0.42 (CI: 0.34 – 0.52; VE=58% [48% - 66%]) during Omicron periods. Incidence rates (IR) per 1000 person-years for hospitalization before delta were 0.75 among unvaccinated and zero among vaccinated. During Delta, the IR was 6.64 for unvaccinated and zero for fully vaccinated and boosted. During Omicron, the IR was 10.27 for unvaccinated, zero for fully vaccinated < 150 days prior, 2.48 for fully vaccinated ≥ 150 days prior and zero for those boosted. CONCLUSION: COVID-19 vaccines protect against infection and hospitalization among pregnant people. However, vaccine effectiveness against infection wanes over time and was lower during Omicron. Booster doses are necessary for continuous protection. DISCLOSURES: All Authors: No reported disclosures. Oxford University Press 2022-12-15 /pmc/articles/PMC9752373/ http://dx.doi.org/10.1093/ofid/ofac492.135 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Zerbo, Ousseny
Thomas Ray, G
Goddard, Kristin
Layefsky, Evan
Fireman, Bruce
Klein, Nicola P
2297. COVID-19 Vaccine Effectiveness Among Pregnant People
title 2297. COVID-19 Vaccine Effectiveness Among Pregnant People
title_full 2297. COVID-19 Vaccine Effectiveness Among Pregnant People
title_fullStr 2297. COVID-19 Vaccine Effectiveness Among Pregnant People
title_full_unstemmed 2297. COVID-19 Vaccine Effectiveness Among Pregnant People
title_short 2297. COVID-19 Vaccine Effectiveness Among Pregnant People
title_sort 2297. covid-19 vaccine effectiveness among pregnant people
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752373/
http://dx.doi.org/10.1093/ofid/ofac492.135
work_keys_str_mv AT zerboousseny 2297covid19vaccineeffectivenessamongpregnantpeople
AT thomasrayg 2297covid19vaccineeffectivenessamongpregnantpeople
AT goddardkristin 2297covid19vaccineeffectivenessamongpregnantpeople
AT layefskyevan 2297covid19vaccineeffectivenessamongpregnantpeople
AT firemanbruce 2297covid19vaccineeffectivenessamongpregnantpeople
AT kleinnicolap 2297covid19vaccineeffectivenessamongpregnantpeople